Background {#Sec1}
==========

*Staphylococcus aureus* is a well-recognized human pathogen that is implicated in a wide array of superficial, invasive and toxigenic infections \[[@CR1]\]. Meta-analyses of published studies have provided evidence that *S. aureus* nasal carriage is an important risk factor for subsequent infection among patients with surgical site infections and atopic dermatitis \[[@CR2], [@CR3]\]. Other high-risk groups include patients colonized with methicillin-resistant *Staphylococcus aureus* (MRSA) undergoing dialysis, and patients admitted in the intensive care unit \[[@CR4], [@CR5]\]. Consequently, infection prevention strategies such as nasal decolonization are employed to minimize the occurrence of staphylococcal infection and reduce the risk of transmission in healthcare settings \[[@CR6], [@CR7]\]. Mupirocin (2%) nasal ointment alone or in combination with 4% chlorhexidine (CHG) based body wash is considered as the main decolonization strategy for *S. aureus* carriage \[[@CR8], [@CR9]\]. Mupirocin is a naturally occurring antibiotic produced by *Pseudomonas fluorescens* that interferes with protein synthesis by competitive inhibition of the bacterial isoleucyl-tRNA synthetase (IRS) \[[@CR10], [@CR11]\]. It gained prominence in the mid-1990s for the eradication of *S. aureus* nasal carriage due to its effectiveness, safety and cost \[[@CR12]\].

Mupirocin-resistant (mupR) *S. aureus* was first reported in the United Kingdom in 1987 \[[@CR13]\]. Since then, it has been reported in several countries worldwide \[[@CR14]--[@CR17]\]. The emergence of mupR *S. aureus* has been associated with unrestricted policies and use of mupirocin for long periods in health care settings \[[@CR8], [@CR18]\]. Decolonization failure in patients with *S. aureus* carriage is associated with high-level mupirocin resistance (HmupR - minimum inhibitory concentration \[MIC\]: ≥512 μg/ml), while that of low-level mupirocin resistance (LmupR -- MIC: 8-64 μg/ml) is still unclear \[[@CR7], [@CR19]\]. LmupR is mediated through point mutation (largely V588F and V631F) in the native isoleucyl-tRNA synthetase (*ileS*) gene \[[@CR20]\]. In contrast, HmupR is mainly attributed to the acquisition of plasmids with the *mupA* (or *ileS2*) gene encoding an additional IRS with no affinity for mupirocin \[[@CR11], [@CR21]\]. Another determinant for HmupR is the acquisition of a plasmid-mediated *mupB* gene \[[@CR22]\].

There is no data summarizing reports on screening, prevalence, characterization, and geographic spread of mupR *S. aureus* in Africa. This systematic review evaluated published articles that assessed for mupirocin resistance in African *S. aureus* isolates. The findings from this systematic review highlight the need to develop an early warning system, including harmonized strategies for the prompt screening and identification of mupR *S. aureus* in Africa.

Methods {#Sec2}
=======

Literature search strategy {#Sec3}
--------------------------

The relevant English articles from human and animal investigations were retrieved by three authors (YA, SA, and AS) from five electronic databases (EBSCOhost, Google Scholar, ISI Web of Science, MEDLINE, and Scopus). The search terms for each database are reported in Table [1](#Tab1){ref-type="table"}. The literature search was concluded on 3 August 2016.Table 1Keywords used to identify eligible studies available in five biomedical databasesDatabaseSearch periodSearch strategyMEDLINE via PubMed\
EBSCOhost via Academic Search premier, Africa-Wide information and CINAHL1974 - August 2016\
1982 - August 2016(Staphylococcus aureus OR S. aureus)\
AND\
(Mupirocin)\
AND\
(Algeria OR Angola OR Benin OR Botswana OR Burkina Faso OR "Burkina Faso" OR Burkina Fasso OR Upper Volta OR "Upper Volta" OR Burundi OR Cameroon OR Cape Verde OR "Cape Verde" OR Central African Republic OR Chad OR Comoros OR "Iles Comores" OR Iles Comores OR Comoro Islands OR "Comoro Islands" OR Congo OR Democratic Republic Congo OR "Democratic Republic of the Congo" OR Zaire OR Djibouti OR Egypt OR Equatorial Guinea OR "Equatorial Guinea" OR Eritrea OR Ethiopia OR Gabon OR Gambia OR Ghana OR Guinea OR Guinea Bissau OR "Guinea Bissau" OR Ivory Coast OR "Ivory Coast" OR Cote d'Ivoire OR "Cote d'Ivoire" OR Kenya OR Lesotho OR Liberia OR Libya OR Libia OR Jamahiriya OR Jamahiryia OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Ile Maurice OR "Ile Maurice" OR Morocco OR Mozambique OR Moçambique OR Namibia OR Niger OR Nigeria OR Rwanda OR Sao Tome OR "Sao Tome" OR Senegal OR Seychelles OR Sierra Leone OR "Sierra Leone" OR Somalia OR South Africa OR "South Africa" OR Sudan OR South Sudan OR "South Sudan" OR Swaziland OR Tanzania OR Tanganyika OR Zanzibar OR Togo OR Tunisia OR Uganda OR Western Sahara OR "Western Sahara" OR Zambia OR Zimbabwe OR Africa OR Africa\* OR Southern Africa OR West Africa OR Western Africa OR Eastern Africa OR East Africa OR North Africa OR Northern Africa OR Central Africa OR Sub Saharan Africa OR Subsaharan Africa OR Sub-Saharan Africa)\
NOT\
(Guinea pig\* OR "Guinea pig\*" OR Aspergillus niger OR "Aspergillus niger" OR Europe\* OR America\* OR Asia\*)ISI Web of Science1950 - August 2016Scopus from SciVerse1982 - August 2016(Staphylococcus aureus OR S. aureus)\
AND\
(Mupirocin)\
AND\
(Africa)^a^Google Scholar\*\*(Staphylococcus aureus OR S. aureus)\
AND\
(Mupirocin)\
AND\
(Name of each African country)\
Examples\
(Staphylococcus aureus OR S. aureus) AND (Mupirocin) AND (Algeria)\
(Staphylococcus aureus OR S. aureus) AND (Mupirocin) AND (Zimbabwe)^a^The African countries were manually selected (as recommended by Scopus database) to exclude studies from other continents\*\*The Google Scholar search was conducted between July-September 2015

Eligible article identification {#Sec4}
-------------------------------

The identification of the eligible articles was conducted according to the guidelines for preferred reporting items for systematic reviews and meta-analyses (PRISMA) \[[@CR23]\]. We defined an eligible article as a peer-reviewed publication that (i) included mupirocin in the antibiotic susceptibility testing of *S. aureus* isolates, and (ii) employed phenotypic ((disc diffusion, E-test, minimum inhibitory concentration (MIC), VITEK and other automated methods)), and/or molecular ((conventional or real-time polymerase chain reaction (PCR)) techniques. International multicentre studies that included African countries were also eligible for inclusion.

Data extraction and analysis {#Sec5}
----------------------------

The relevant data were extracted from each of the eligible articles included in this systematic review. A study that analysed *S. aureus* isolates from another investigation but answered a different research question were both considered as one study (Table [2](#Tab2){ref-type="table"}). We performed three levels of analysis (Fig. [1](#Fig1){ref-type="fig"}). First, to understand the characteristics and geographic spread of mupR *S. aureus* in Africa, studies that included mupirocin in the antibiotic susceptibility testing and employed phenotypic and/or molecular techniques were identified. Secondly, the prevalence of *S. aureus* with the *mupA* gene, isolates that expressed LmupR and HmupR, and mupR-MRSA in Africa were derived from each eligible study as follows:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ MupA\hbox{-} \mathrm{positive}\ S.\kern0.5em aureus=\frac{\mathrm{Number}\ \mathrm{of}\  MupA\hbox{-} \mathrm{positive}\ S.\kern0.5em aureus\ \mathrm{isolates}}{\mathrm{Total}\ \mathrm{number}\ \mathrm{of}\ \mathrm{isolates}\ \mathrm{screened}\ \mathrm{with}\ \mathrm{mupirocin}} $$\end{document}$$$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ S.\kern0.5em aureus\ \mathrm{that}\ \mathrm{expressed}\ \mathrm{LmupR}=\frac{\mathrm{Number}\ \mathrm{of}\ S.\kern0.5em aureus\ \mathrm{isolates}\ \mathrm{with}\ \mathrm{LmupR}}{\mathrm{Total}\ \mathrm{number}\ \mathrm{of}\ \mathrm{isolates}\ \mathrm{screened}\ \mathrm{with}\ \mathrm{mupirocin}} $$\end{document}$$$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ S.\kern0.5em aureus\ \mathrm{that}\ \mathrm{expressed}\ \mathrm{HmupR}=\frac{\mathrm{Number}\ \mathrm{of}\ S.\kern0.5em aureus\ \mathrm{isolates}\ \mathrm{with}\ \mathrm{HmupR}}{\mathrm{Total}\ \mathrm{number}\ \mathrm{of}\ \mathrm{isolates}\ \mathrm{screened}\ \mathrm{with}\ \mathrm{mupirocin}} $$\end{document}$$$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \mathrm{MupR}\hbox{-} \mathrm{MRSA}=\frac{\mathrm{Number}\ \mathrm{of}\ \mathrm{mupR}\hbox{-} \mathrm{MRSA}\ \mathrm{isolates}}{\mathrm{Total}\ \mathrm{number}\ \mathrm{of}\ \mathrm{isolates}\ \mathrm{screened}\ \mathrm{with}\ \mathrm{mupirocin}} $$\end{document}$$Table 2Characteristics of the 43 eligible studies on screening for mupirocin resistance in *Staphylococcus aureus* from various sources in AfricaRegionCountryStudy PeriodSettingSampleMethod for testing resistance to mupirocinGuideline (year of publication)Published reports for detection of mupR *S. aureus*Number of *S. aureus* isolates screened with mupirocinMupirocin resistant isolatesReferenceSourceTypeNumber (%)Number MRSA (%)Number LmupR/HmupRNumber *mupA* gene + LMupR/HmupR (Method)North AfricaAlgeria2005--2007C & HHumanPus, venous catheter, tracheal aspirate, punction fluid, blood, urineDisk diffusion VITEK-2CLSI (NA)--190 (0)0 (0)----\[[@CR47]\]Egypt2005--2006C & HHumanNADisk diffusionNCCLS (2003)--640 (0)0 (0)----\[[@CR28]\]Egypt2008--2009C & HHumanSkin and soft tissue, post-operative wound swabDisk diffusionCLSI (2007)--3861 (0.3)NANA--\[[@CR29]\]Egypt2007--2008CHumanPus, sputum, catheter, blood, urine, wound abscessBroth dilutionCLSI (2005)--210 (0)0 (0)----\[[@CR58]\]Egypt2010HHumanSputum, blood, catheter, traumatic wound, urineE-test--Kresken et al., (2004)8630 (34.9)30 (34.9)25/52/3 (PCR)\[[@CR30]\]Egypt2012HHumanWound discharge, blood, body fluid aspirate, urine, faeces, sputum, nasal, throat, ear and genital swabDisk diffusion Agar dilutionCLSI (2007)--1500 (0)0 (0)----\[[@CR40]\]Egypt2012--2013HHumanNasal swabDisk diffusionCLSI (2011)--393 (7.7)3 (3.7)NA--\[[@CR31]\]Egypt2013--2015HHumanPus & Wound swabAgar dilutionCLSI (2011)--7313 (17.8)13 (17.8)5/80/6 (PCR)\[[@CR52]\]LibyaNAHHumanSkin swabDisk diffusionNA--400 (0)NA----\[[@CR61]\]Libya2008--2009HHuman & EnvironmentNADisk diffusionBSAC (2008)--8613 (15.1)13 (8.1)NA--\[[@CR56]\]Libya2009HHumanNasal swabDisk diffusion Agar dilutionBSAC (2008)--1095 (4.6)5 (4.6)4/1--\[[@CR57]\]Morocco2008-HHumanNasal swabDisk diffusionCA-SFM (2007)--810 (0)0 (0)----\[[@CR62]\]Tunisia2008--2009CHumanNasal swabDisk diffusionCLSI (2008)--550 (0)0 (0)----\[[@CR41]\]Tunisia2003--2005CHumanPus, blood, articular puncture, venous catheterPhoenix Automated Microbiology SystemCA-SFM (2006)--64NANA----\[[@CR59]\]Tunisia2013HHumanWound abscessDisk diffusionCA-SFM (2013)--8NANA----\[[@CR60]\]Tunisia2010CAnimal (Sheep)Nasal swabDisk diffusionCLSI (2010)--730 (0)0 (0)----\[[@CR42]\]Tunisia2010CAnimal (Donkeys)Nasal swabDisk diffusionCLSI (2010)--500 (0)0 (0)----\[[@CR43]\]West AfricaGhana2011--2012HHumanNasal swabDisk diffusionEUCAST (2012)--1051 (0.9)0 (0)0/1--\[[@CR54]\]Ghana2011--2012CHumanNasal swabDisk diffusionEUCAST (2012)--1240 (0)0 (0)----\[[@CR67]\]Ghana2010--2013C & HHumanNABroth microdilutionEUCAST (NA)--304 (13.3)4 (13.3)4/00/0 (DNA microarray)\[[@CR55]\]Ghana2012--2013CHumanNasal & Wound swabVITEK-2EUCAST (NA)--910 (0)0 (0)----\[[@CR68]\]Nigeria\*NANAHumanNADisk diffusionNA--10 (0)0 (0)----\[[@CR80]\]Nigeria\*2002--2004HHumanWound, blood, ear, eye, urineDisk diffusion--Udo et al., (1999)2001 (0.5)0 (0)0/10/1 (PCR)\[[@CR53]\]Nigeria2006CHumanNasal swabDisk diffusionCLSI (2005)--10112 (11.9)NANA--\[[@CR44]\]Nigeria2007HHumanNADisk diffusionCLSI (NA)--960 (0)0 (0)----\[[@CR48]\]Nigeria\*NAHHumanWound swab, blood, urine, endotracheal aspirateDisk diffusion E-testNCCLS (2003)--110 (0)0/10/1 (PCR)\[[@CR45]\]Nigeria2009HHumanWound, sputum, semen, nasal swabBroth microdilutionDIN 58940 (2004)--680 (0)0 (0)----\[[@CR63]\]Nigeria2010HHumanNAVITEK-2----510 (0)0 (0)----\[[@CR64]\]Nigeria2009--2011HHumanAspirate, blood, ear, eye, vaginal discharge, sputum, wounds, urine, nasal swabDisk diffusionCLSI (NA)--620 (0)0 (0)----\[[@CR49]\]Nigeria2010--2011HHumanNAVITEK-2EUCAST (NA)--2900 (0)0 (0)----\[[@CR65]\]Nigeria2008--2010CAnimal (Bats)Faecal swabDisk diffusion--Udo et al., (1999)1070 (0)0 (0)----\[[@CR66]\]Nigeria2006--2007C & HAnimal (Bovine) & (Ovine)Nasal & skin swabDisk diffusion--Udo et al., (1999)1730 (0)0 (0)----\[[@CR35]\]Nigeria2012CHuman AnimalNasal swab MilkDisk diffusionCLSI (2006)--10 Humans 77 Animals33 (37.9)NA0/33--\[[@CR36]\]Central AfricaGabon2009C & HHumanNasal, axillae, inguinal swabVITEK-2----50 (0)0 (0)----\[[@CR69]\]São Tomé & Príncipe2010--2012HHumanNasal swabDisk diffusionBSAC (NA)--550 (0)0 (0)----\[[@CR70]\]East AfricaEthiopiaNAH & RCockroachCockroach Body surface/GutDisk diffusion--Jorgenson et al., (1999)1717 (100)NANA--\[[@CR37]\]Kenya2011HHumanNasal and axillary skin swabVITEK-2CLSI (2012)--860 (0)0 (0)----\[[@CR71]\]Kenya2011--2013HHumanPus, blood, urineVITEK-2CLSI (2010)--7310 (0)0 (0)----\[[@CR72]\]KenyaNACAnimal (Camel)Raw camel milkDisk diffusion Broth microdilutionCLSI (2008)--470 (0)0 (0)----\[[@CR38]\]South AfricaSouth Africa1996HHumanWound, urine, skin and bloodDisk diffusionNCCLS (2000)--2365 (2.1)NANA--\[[@CR46]\]South Africa\*\*2001--2003HHumanWound, sputum, bloodDisk diffusion--Udo et al., (1999)22716 (7.0)15 (6.6)14/20/2 (PCR)\[[@CR50]\]South Africa2005--2006HHumanBlood, pus & skin wound, cerebrospinal fluidDisk diffusion E-test--Udo et al., (2006)248123 (49.6)123 (49.6)117/6--\[[@CR32]\]South Africa\*\*NAHHumanWound swab, blood, urine, endotracheal aspirateDisk diffusion E-testNCCLS (2003)--1616 (100)14 (87.5)14/20/2 (PCR)\[[@CR45]\]South Africa2013HHumanTissue, blood, cerebrospinal fluid, wound swabDisk diffusion VITEK-2CLSI (2012)--997277 (27.8)NA43/2340/5 (Real time PCR)\[[@CR33]\]South Africa2010--2012HHumanBloodMicroscan (MIC Panel Type 33)CLSI (2015)--2709236 (8.7)202 (7.5)NA--\[[@CR51]\]South Africa2009--2010HHuman & EnvironmentNasal & hand swab, dialysate fluid, surface swab, air samplesVITEK-2----134 (30.8)4 (30.8)0/4--\[[@CR34]\]KEY: mupR *S. aureus*: mupirocin resistant *Staphylococcus aureus*; *LmupR* low-level mupirocin resistance, *HmupR* high-level mupirocin resistance, *mupA* mupirocin resistance gene, *MIC* Minimum inhibitory concentration, *BSAC* British Society for Antimicrobial Chemotherapy, *CA-SFM* Comité de l'Antibiogramme de la Société Française de Microbiologie, *CLSI* Clinical and Laboratory Standards Institute, *DIN 58940* Deutsches Institut für Normung DIN 58940, *EUCAST* European Committee on Antimicrobial Susceptibility Testing, *NCCLS* National Committee for Clinical Laboratory Standards, *PCR* Polymerase Chain Reaction; − Not determined, *NA* Not available, *H* Hospital, *C* Community, *R* Restaurant\*Separate reports that analyzed the same isolates but answered different questions (considered as one single study) in Nigeria; \*\*: Separate reports that analyzed the same isolates but answered different questions (considered as one single study) in South Africa.Reference \[[@CR45]\] is recorded in Nigeria and South Africa, but the isolates were derived from studies in Nigeria \[[@CR53]\] and South Africa \[[@CR50]\], respectivelyOther published reports applied for the detection of mupR *S. aureus* in Africa1. Jorgenson JH, Turnidge JD, Washington JA. Dilution and disc diffusion method. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of Clinical Microbiology, 7th edition. American Society for Microbiology, Washington DC, 1999. p. 1526--1543. Adapted from NCCLS: National Committee for Clinical Laboratory Standards 1997. Approved Standard M2-A6; National Committee for Clinical Laboratory Standards 1999. Approved Standard M100-S9.2. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA. Prevalence of mupirocin resistance in clinical isolates of *Staphylococcus aureus* and *Staphylococcus epidermidis*. Results of the antimicrobial resistance surveillance study of the Paul-Ehrlich Society for Chemotherapy, 2001. Int J Antimicrob Agents, 2004, 23:577--81. The widely accepted breakpoints: ≤4 mg/l (susceptible), 8--256 mg/l (low-level resistance) and ≥ 512 mg/l (high-level resistance) was utilized in this study.3. Udo EE, Farook VS, Mokadas EM, Jacob LE, Sanyal SC. Molecular fingerprinting of mupirocin-resistant methicillin-resistant *Staphylococcus aureus* from a burn unit. Int J Infect Dis, 1999,3:82--7. Growth within a 14-mm zone of inhibition with the 5 μg mupirocin disk detected low-level resistance, while growth to the edge of the 200 μg mupirocin disk indicated high-level resistance.4. Udo EE, Al-Sweih N, Mokaddas E, Johny M, Dhar R, Gomaa HH, Al-Obaid I, Rotimi VO. Antibacterial resistance and their genetic location in MRSA isolated in Kuwait hospitals, 1994--2004. BMC Infect Dis, 2006;6:168. The widely accepted breakpoints:≤4 mg/l (susceptible), 8--256 mg/l (low-level resistance) and ≥ 512 mg/l (high-level resistance) was utilized in this study.Fig. 1The Preferred Reporting Items for Systematic Review and Meta-analysis flow diagram

Thirdly, to estimate the prevalence of mupR *S. aureus* in humans, studies that employed at least one of the screening methods with defined breakpoint for mupirocin resistance were included in the meta-analysis. The StatsDirect statistical software version 3.0.165 (England: StatsDirectLtd.2016) was utilized to assess the heterogeneity of the eligible studies included in the meta-analysis (Cochran Q-test) \[[@CR24]\], and to ascertain the inconsistency across the studies (I2 statistic) \[[@CR25]\]. The random effects model was used to determine the pooled prevalence of mupR *S. aureus* in Africa. The criterion for statistical significance for heterogeneity was set at alpha = 0.05. The risk of publication bias was assessed and visualized by a Funnel plot \[[@CR26], [@CR27]\].

Results {#Sec6}
=======

Eligible studies from electronic database search {#Sec7}
------------------------------------------------

We identified 43 reports (Table [1](#Tab1){ref-type="table"}) of which 34 studies investigated only human samples. The remaining nine studies assessed samples from only animals (*n* = 5), human and environmental sources (*n* = 2), human and animal sources (*n* = 1), and cockroaches (n = 1). Most of the eligible studies (32/43; 74%) were obtained from EBSCOhost, ISI Web of Science, MEDLINE, and Scopus. The remaining studies (11/43; 26%) were obtained only through Google Scholar and consisted of studies conducted in Egypt \[[@CR28]--[@CR31]\], South Africa \[[@CR32]--[@CR34]\], Nigeria \[[@CR35], [@CR36]\], Ethiopia \[[@CR37]\] and Kenya \[[@CR38]\].

Screening and identification of mupR *S. aureus* in Africa {#Sec8}
----------------------------------------------------------

Only 12 of the 54 (22%) African countries reported data on screening for mupR *S. aureus* (Fig. [2](#Fig2){ref-type="fig"}). The first published article indicated that mupirocin had been in use in Africa, at least from the late 1980s \[[@CR39]\]. Most of these studies (28/43; 65%) were conducted in Nigeria (10/43; 23%), Egypt (7/43; 16%), South Africa (6/43; 14%) and Tunisia (5/43; 12%) (Fig. [2](#Fig2){ref-type="fig"}). MupR *S. aureus* was mainly identified through the disk diffusion method (29/43; 67%). The guidelines by the Clinical and Laboratory Standards Institute (CLSI), previously known as National Committee for Clinical Laboratory Standards (NCCLS), were broadly used in Africa (Table [2](#Tab2){ref-type="table"}). However, a number of studies \[[@CR28], [@CR29], [@CR31], [@CR33], [@CR36], [@CR40]--[@CR46]\] utilized the disk diffusion method with CLSI guidelines that had no zone diameter breakpoint for mupirocin. Moreover, some studies \[[@CR47]--[@CR49]\] did not provide information on the year of publication of the CLSI guidelines. MupR *S. aureus* was reported in six African countries including South Africa \[[@CR32]--[@CR34], [@CR46], [@CR50], [@CR51]\], Egypt \[[@CR29]--[@CR31], [@CR52]\], Nigeria \[[@CR36], [@CR44], [@CR53]\], Ghana \[[@CR54], [@CR55]\], Libya \[[@CR56], [@CR57]\] and Ethiopia \[[@CR37]\] (Fig. [2](#Fig2){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}). The *mupA*-positive *S. aureus* was detected in five studies from Egypt \[[@CR30], [@CR52]\], South Africa \[[@CR33], [@CR50]\] and Nigeria \[[@CR53]\]. LmupR and HmupR were both reported in six human studies conducted in South Africa \[[@CR32], [@CR33], [@CR50]\], Egypt \[[@CR30], [@CR52]\] and Libya \[[@CR57]\]. The mupR-MRSA isolates were identified in South Africa \[[@CR32], [@CR34], [@CR50], [@CR51]\], Egypt \[[@CR30], [@CR31], [@CR52]\], Libya \[[@CR56], [@CR57]\], Ghana \[[@CR55]\] and Nigeria \[[@CR36]\] (Table [3](#Tab3){ref-type="table"}). MupR-MRSA was not reported from MRSA isolates recovered from studies conducted in Egypt \[[@CR28], [@CR58]\], Tunisia \[[@CR59], [@CR60]\] and Algeria \[[@CR47]\].Fig. 2Studies on screening for mupirocin-resistant *Staphylococcus aureus* in AfricaTable 3Prevalence of mupirocin-resistant *S. aureus* from various sources in Africa based on phenotypic and molecular methodsMupirocin resistanceCountrySourceNumber positive/Total tested (%)PhenotypicMolecularGuidelines or reportsReferenceAgar DilutionBroth microdilutionDisk diffusionE-testMicroscan systemVITEKPCRMicro arrayBSACCLSIEUCASTOther reports*MupA*-positive *S. aureus*EgyptHuman5/86 (5.8)------√----√--------√^a^\[[@CR30]\]EgyptHuman6/73 (8.2)√----------√----√----\[[@CR52]\]NigeriaHuman1/200 (0.5)----√------√--------√^b^\[[@CR53]\]South AfricaHuman2/227 (0.9)----√------√--------√^b^\[[@CR50]\]South AfricaHumanNA----√----√√----√----\[[@CR33]\]LmupR *S. aureus*EgyptHuman25/86 (29.1)------√----√--------√^a^\[[@CR30]\]EgyptHuman5/73 (6.8)√----------√----√----\[[@CR52]\]GhanaHuman4/30 (13.3)--√----------√----√--\[[@CR55]\]LibyaHuman4/109 (3.7)√--√----------√------\[[@CR57]\]South AfricaHuman14/227 (6.2)----√----------------√^b^\[[@CR50]\]South AfricaHuman117/248 (47.2)----√√--------------√^c^\[[@CR32]\]South AfricaHuman43/997 (4.3)----√----√------√----\[[@CR33]\]South AfricaHuman & Environment4/13 (30.8)----------√------------\[[@CR34]\]HmupR *S. aureus*EgyptHuman5/86 (5.8)------√----√--------√^a^\[[@CR30]\]EgyptHuman8/73 (11)√----------√----√----\[[@CR52]\]GhanaHuman1/105 (1.0)----√--------------√--\[[@CR54]\]LibyaHuman1/109 (0.9)√--√----------√------\[[@CR57]\]NigeriaHuman1/200 (0.5)----√------√--------√^b^\[[@CR53]\]NigeriaHuman12/101 (11.9)----√------------√----\[[@CR44]\]NigeriaHuman & Animal33/87 (37.9)----√------------√----\[[@CR36]\]South AfricaHuman2/227 (0.9)----√------√--------√^b^\[[@CR50]\]South AfricaHuman6/248 (2.4)----√√--------------√^c^\[[@CR32]\]South AfricaHuman234/997 (23.5)----√----√------√----\[[@CR33]\]mupR-MRSAEgyptHuman30/86 (34.9)------√----√--------√^a^\[[@CR30]\]EgyptHuman3/39 (7.7)----√------------√----\[[@CR31]\]EgyptHuman13/73 (17.8)√----------√----√----\[[@CR52]\]GhanaHuman4/30 (13.3)--√----------√----√--\[[@CR55]\]LibyaHuman13/86 (15.1)----√----------√------\[[@CR56]\]LibyaHuman5/109 (4.6)√--√----------√------\[[@CR57]\]NigeriaHuman & Animal33/87 (37.9)----√------------√----\[[@CR36]\]South AfricaHuman15/227 (6.6)----√------√--------√^b^\[[@CR50]\]South AfricaHuman123/248 (49.6)----√√--------------√^c^\[[@CR32]\]South AfricaHuman202/2709 (7.5)--------√--------√√--\[[@CR51]\]South AfricaHuman & Environment4/13 (30.8)----------√------------\[[@CR34]\]KEY: *BSAC* British Society for Antimicrobial Chemotherapy, *CLSI* Clinical and Laboratory Standards Institute, *EUCAST* European Committee on Antimicrobial Susceptibility Testing, *NA* Not Available, *PCR* Polymerase Chain Reaction, √: test was performed. -: test was not performed^a^The widely accepted breakpoints: ≤4 mg/l (susceptible), 8--256 mg/l (low-level resistance) and ≥ 512 mg/l (high-level resistance) was utilized in this study: Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA. Prevalence of mupirocin resistance in clinical isolates of *Staphylococcus aureus* and *Staphylococcus epidermidis*. Results of the antimicrobial resistance surveillance study of the Paul-Ehrlich Society for Chemotherapy, 2001. Int J Antimicrob Agents, 2004, 23:577--81. ^b^Growth within a 14-mm zone of inhibition with the 5 μg mupirocin disk detected low-level resistance, while growth to the edge of the 200 μg mupirocin disk indicated high-level resistance according to: Udo EE, Farook VS, Mokadas EM, Jacob LE, Sanyal SC. Molecular fingerprinting of mupirocin-resistant methicillin-resistant *Staphylococcus aureus* from a burn unit. Int J Infect Dis, 1999,3:82--7. ^c^The widely accepted breakpoints: ≤4 mg/l (susceptible), 8--256 mg/l (low-level resistance) and ≥ 512 mg/l (high-level resistance) was utilized in this study: Udo EE, Al-Sweih N, Mokaddas E, Johny M, Dhar R, Gomaa HH, Al-Obaid I, Rotimi VO. Antibacterial resistance and their genetic location in MRSA isolated in Kuwait hospitals, 1994--2004. BMC Infect Dis, 2006;6:168

An assessment of data on mupR *S. aureus* at the regional level is described as follows (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Geographic distribution of mupirocin-resistant (mupR) *Staphylococcus aureus* in Africa. Countries (in green) in which mupR *S. aureus* have been investigated but not reported. Countries (in red) in which mupR *S. aureus* have been investigated and reported

North Africa {#Sec9}
------------

Seventeen eligible studies were recorded from this region, including Egypt \[[@CR28]--[@CR31], [@CR40], [@CR52], [@CR58]\], Tunisia \[[@CR41]--[@CR43], [@CR59], [@CR60]\], Libya \[[@CR56], [@CR57], [@CR61]\], Algeria \[[@CR47]\] and Morocco \[[@CR62]\]. MupR *S. aureus* was reported in six studies conducted in two North African countries: Egypt \[[@CR29]--[@CR31], [@CR52]\] and Libya \[[@CR56], [@CR57]\]. PCR detection of the *mupA* gene was performed in only two studies conducted in Egypt \[[@CR30], [@CR52]\]. In addition, one of the reports identified two *mupA* positive MRSA that exhibited LmupR \[[@CR30]\]. MupR *S. aureus* was not detected in Tunisia \[[@CR41]--[@CR43], [@CR59], [@CR60]\], Algeria \[[@CR47]\], and Morocco \[[@CR62]\].

West Africa {#Sec10}
-----------

*S. aureus* resistance to mupirocin was investigated in Nigeria \[[@CR35], [@CR36], [@CR44], [@CR48], [@CR49], [@CR53], [@CR63]--[@CR66]\] and Ghana \[[@CR54], [@CR55], [@CR67], [@CR68]\]. Only two studies from Ghana reported on mupR *S. aureus* \[[@CR54], [@CR55]\]. In Nigeria, three studies (including two from only human sources and one from both animal and human samples, respectively) reported on *S. aureus* isolates that demonstrated HmupR \[[@CR36], [@CR44], [@CR53]\].

Central Africa {#Sec11}
--------------

MupR *S. aureus* was not detected in studies conducted in Gabon \[[@CR69]\], and São Tomé and Príncipe \[[@CR70]\].

East Africa {#Sec12}
-----------

In this review, we identified four eligible studies conducted in Kenya \[[@CR38], [@CR71], [@CR72]\] and Ethiopia \[[@CR37]\]. A report on the role of cockroaches as potential vectors of foodborne pathogens in Ethiopia identified 17 mupR *S. aureus* isolates \[[@CR37]\]. All the *S. aureus* isolates (one animal and two human studies) from Kenya were susceptible to mupirocin \[[@CR38], [@CR71], [@CR72]\].

Southern Africa {#Sec13}
---------------

The six studies reported in this geographical area were from South Africa and consisted of two single centre studies \[[@CR34], [@CR46]\] and four multicenter studies \[[@CR32], [@CR33], [@CR50], [@CR51]\]. MupR *S. aureus* was identified in all the reports, while *mupA*-positive *S. aureus* isolates were noted in only two studies \[[@CR33], [@CR50]\].

Prevalence of mupR *S. aureus* in Africa {#Sec14}
----------------------------------------

The random-effects pooled prevalence of mupR *S. aureus* in Africa is 14% (95% CI =6.8 to 23.2%). This was calculated based on 11 heterogeneous human studies (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}) conducted in South Africa \[[@CR32], [@CR33], [@CR50], [@CR51]\], Ghana \[[@CR54], [@CR55]\], Egypt \[[@CR30], [@CR52]\], Libya \[[@CR56], [@CR57]\] and Nigeria \[[@CR53]\]. In Africa, the proportion of *S. aureus* isolates with the *mupA* gene, and those that expressed LmupR and HmupR ranged between 0.5 and 8%, 4 and 47%, 0.5 and 38%, respectively. The frequency of mupR-MRSA isolates ranged between 5 and 50% (Table [3](#Tab3){ref-type="table"}).Fig. 4Bias assessment (Funnel) plot for studies assessing rates of mupirocin-resistant *Staphylococcus aureus* in Africa. Random effects (DerSimonian-Laird). Pooled proportion = 0.139303 (95% CI = 0.067511 to 0.23165). Bias indicators, Begg-Mazumdar: Kendall's tau = 0.2 *P* = 0.4454, Egger: bias = 4.771137 (95% CI = −2.517874 to 12.060148) *P* = 0.1728, Harbord: bias = 2.014783 (92.5% CI = −5.90181 to 9.931377) *P* = 0.6208Fig. 5Pooled estimate of proportions (human studies) for mupirocin-resistant *Staphylococcus aureus* in Africa

Association of MupR *S. aureus* with mupirocin use in Africa {#Sec15}
------------------------------------------------------------

There is no data on the use of mupirocin as an agent for *S. aureus* decolonization and its association with mupR *S. aureus* in Africa.

MupR *S. aureus* and biofilm production {#Sec16}
---------------------------------------

A report from Egypt noted that mupR-MRSA were moderate to strong biofilm producers \[[@CR52]\].

MupR *S. aureus* and co-resistance to other antibiotics {#Sec17}
-------------------------------------------------------

In this systematic review, two studies (conducted in Egypt and South Africa) showed that mupR *S. aureus* was associated with multi-drug resistance \[[@CR30], [@CR33]\].

Molecular characterization of mupR *S. aureus* in Africa {#Sec18}
--------------------------------------------------------

Only three studies provided molecular data on mupR *S. aureus* in Africa \[[@CR45], [@CR54], [@CR55]\]. A report provided evidence of a 35 kb (non-conjugative) and 41.1 kb (conjugative) plasmid encoding *mupA* in *S. aureus* isolates from Nigeria and South Africa \[[@CR45]\]. It also described an MRSA clone that demonstrated LmupR in South Africa. LmupR was also identified among MRSA isolates assigned with ST36, ST88, and ST789 in Ghana \[[@CR55]\]. A cross-sectional *S. aureus* study identified a methicillin susceptible *S. aureus* (MSSA) strain with HmupR from a 51-year-old hospital staff in Ghana \[[@CR54]\]. Molecular characterization indicated that the strain (*spa* type t4805) was PVL-positive.

Discussion {#Sec19}
==========

This is the first systematic review on mupR *S. aureus* in Africa and clearly showed the paucity of data on the continent. Nevertheless, this study indicated a high prevalence ((14% (95% CI =6.8 to 23.2)) of mupR *S. aureus* in Africa. These observations support the need for mupR *S. aureus* surveillance data to provide information on its epidemiology and clinical significance in Africa. It is noteworthy that Google Scholar was valuable in the identification of several eligible studies \[[@CR28]--[@CR38]\]. We observed that 26% (11/43) of the eligible studies were identified from African journals which were not indexed in commonly used electronic databases. Google Scholar has been considered as a useful supplement with other electronic databases for systematic review search \[[@CR73]\] including recent meta-analyses of published studies on *S. aureus* in Africa \[[@CR74], [@CR75]\].

The phenotypic methods for the screening and identification of mupR *S. aureus* include disc diffusion (two-disc strategy: 5 μg and 200 μg), agar dilution, broth micro-dilution and E-test \[[@CR19]\]. In this study, the disk diffusion method and the CLSI (formerly NCCLS) guidelines were strategies mainly applied to detect mupR *S. aureus* in Africa. However, we observed certain inconsistencies \[[@CR28], [@CR29], [@CR31], [@CR33], [@CR36], [@CR40]--[@CR49]\]. For instance, a number of studies \[[@CR28], [@CR29], [@CR31], [@CR33], [@CR36], [@CR40]--[@CR42], [@CR44]--[@CR46]\] applied the disk diffusion method with the CLSI guidelines that had no breakpoint values for mupirocin. The 2017 CLSI guidelines recommend the use of the 200 μg disk to differentiate between HmupR and the absence of HmupR (i.e. no zone = HmupR; any zone = absence of HmupR) \[[@CR76]\]. The 200 μg disk with a different breakpoint (Susceptible ≥30 mm, Resistance \< 18 mm) is also endorsed for the differentiation between HmupR and the absence of HmupR in the latest versions (accessed 28th May, 2018) of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) and Comité de l'antibiogramme de la Société Française de Microbiologie (CA-SFM) \[[@CR77], [@CR78]\]. The breakpoint values for the detection of LmupR and differentiation from HmupR are not provided in these documents (CA-SFM, CLSI, and EUCAST). Despite this limitation, the disk diffusion method in conjunction with any of these guidelines could at least be valuable for the preliminary screening and identification of HmupR *S. aureus* in Africa. MRSA decolonization failure is of clinical significance as it is often attributed to persistence or re-colonization associated with isolates exhibiting HmupR, while that of LmupR is not clear \[[@CR7], [@CR19], [@CR79]\]. In this review, the prevalence of *S. aureus* that exhibited LmupR, HmupR and mupR-MRSA in Africa was predicated on a range of methods using different guidelines. We suggest that surveillance data from Africa is established on harmonized guidelines to enhance quality assurance and comparison at the continental and global level.

We noted a prevalence of mupR-MRSA ranging between 5 and 50% in Africa (Table [3](#Tab3){ref-type="table"}). This is of serious concern. Specifically, the relationship between mupirocin resistance and MRSA has important consequences on infection control measures and effectiveness of decolonization strategies \[[@CR8]\]. MupR-MRSA could limit the choices available for the control and prevention of healthcare-associated MRSA infections (7, 8). Therefore, surveillance studies are important to investigate the emergence and spread of mupirocin resistance in hospital settings in Africa. This is important among patients at high risk of MRSA infections, including patients in the dermatology, dialysis and the Intensive Care Units. In addition, there is the need for more data on the molecular characterization of mupR *S. aureus* in Africa \[[@CR45], [@CR54], [@CR55]\]. For instance, whole genome sequencing (WGS) will assist in understanding the transmission dynamics of mupR *S. aureus* in Africa. Moreover, WGS data will allow comprehensive investigation of the genetic basis for LmupR mutation (which is largely due to V588F and V631F in the native gene (*ile*S)) and *mupB*-positive *S. aureus* in Africa.

Language bias was the main limitation of this systematic review as we did not include studies published in French, Portuguese, Arabic and Spanish.

Conclusions {#Sec20}
===========

This study showed the need for more epidemiological data to understand the transmission, burden and risk factors associated with mupR *S. aureus* in Africa. In addition, there is a need for data on administration and use of mupirocin in community and hospital setting in Africa. This is important in antibiotic stewardship to mitigate the emergence and spread of mupR *S. aureus* in Africa. Finally, this systematic review highlighted the need for harmonized guidelines to facilitate the comparison of data on mupR *S. aureus* from Africa.
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